Rx Product News (February 2016)

Pharmacy Times, February 2016 Autoimmune Disorders, Volume 82, Issue 2

Read about the new Rx Products featured in February.

Adapt Pharma, Inc

Indication: The FDA has approved Narcan (naloxone hydrochloride) Nasal Spray, an opioid antagonist, for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression. Narcan is intended for immediate administration as emergency therapy in settings where opioids may be present. A single spray of Narcan should be administered to adults or pediatric patients intranasally into 1 nostril. Emergency medical care should be sought immediately after use.

Dosage Form: Nasal spray: 4 mg of naloxone hydrochloride in 0.1 mL

For More Information: adaptpharma.com/products

Tafinlar + MekinistMarketed by: GlaxoSmithKline

Indication: The FDA has approved Tafinlar (dabrafenib) + Mekinist (trametinib) for the treatment of patients with BRAF V600E/K mutation- positive unresectable or metastatic melanoma. The recommended dosage of Tafinlar is 150 mg orally twice daily. The recommended dosage of Mekinist is 2 mg orally once daily. Tafinlar and Mekinist should be taken at least 1 hour before, or at least 2 hours after a meal.

Dosage Form: Tafinlar capsules: 50 and 75 mg; Mekinist tablets: 0.5 and 2 mg

For More Information: us.tafinlarmekinist.com

Pradaxa Marketed by: Boehringer Ingelheim Pharmaceuticals, Inc

Indication: The FDA has approved Pradaxa (dabigatran etexilate mesylate) for the prophylaxis of deep vein thrombosis and pulmonary embolism in patients who have had hip replacement surgery. For this indication, the recommended dosage for patients with a creatinine clearance greater than 30 mL/min is 110 mg orally on the first day, then 220 mg once daily. Pradaxa should be temporarily discontinued before invasive or surgical procedures, when possible, then restarted promptly.

Dosage Form: Capsules: 75, 110, and 150 mg

For More Information: pradaxa.com

FluadMarketed by: Novartis

Indication: The FDA has approved Fluad, an inactivated influenza vaccine, for active immunization against disease caused by influenza virus subtypes A and type B, which are contained in the vaccine. Fluad is approved for use in persons 65 years and older.

Dosage Form: Suspension for injection: 0.5-mL, single-dose, prefilled syringes

For More Information: novartis.com